Antistaphylococcal Betalactam and Emergence of Resistance

Completed

• Conditions: Bacterial Resistance; Methicillin-Sensitive Staphylococcus Aureus Infection

• Registration Number: NCT05939479
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with antistaphylococcal penicillins. Cefazolin has broader spectrum than antistaphylococcal penicillins. The hypothesis of this project is that cefazoline could be responsible for a higher rate of bacterial resistance. The aim is to study the association between the emergence of bacterial resistance and the consumption of cefazolin and antistaphylococcal penicillins.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-01
• Primary Completion: 2023-05-01
• Study Completion: 2023-06-01
• Study First Submitted: 2023-06-23
• Status Verified: 2023-07
• Study First Submitted QC: 2023-07-01
• Last Update Submitted: 2023-07-01
• Study First Posted: 2023-07-11
• Last Update Posted: 2023-07-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 644

Inclusion Criteria

French hospitals which have collected their consumption and resistance data on the French national database named CONSORES (From 2019 to 2022)

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Association between the cefazolin/antistaphylococcal penicillins consumptions and the resistant bacteria emergence	Between the first january 2018 and the 31st december 2022	The total consumption of antibiotics (expressed as number of Defined Daily Doses (DDD) per 1000 inhabitants per day) will be correlate with the resistant bacteria emergence (only incidence for each bacterial strain)

Secondary Outcome Measures

Name	Time	Method
Factors associated with the emergence of resistant bacteria	Between the first january 2018 and the 31st december 2022	Factors associated with the emergence of resistant bacteria will be described by a Cox model: hospital size (number of beds), location in France, activities (intensive care, surgery, etc.), type of antibiotics and intensity of consumption expressed in number of defined daily doses (DDD).
Factors associated with the consumption of antibiotics	Between the first january 2018 and the 31st december 2022	Factors associated with the emergence of resistant bacteria will be described by a Cox model: hospital size (number of beds), location in France, activities (intensive care, surgery, etc.) and type of bacterial strain indentified (resistant or not).
Evolution of resistance in French hospitals	Between the first january 2018 and the 31st december 2022	For each year, bacterial resistance will be described, in France and in each hospital, in the form of a quantitative variable: number of resistant bacterial strains isolated for each year (number of resistant strains / total number of strains).
Evolution of antibiotics consumption in French hospitals	Between the first january 2018 and the 31st december 2022	For each year, antibiotic consumption will be described, in France and in each hospital, in the form of a quantitative variable (expressed as number of Defined Daily Doses (DDD) per 1000 inhabitants per day)

Trial Locations

Locations (1)

Lefevre; 🇫🇷 Nancy, Lorraine, France